

Request for Prior Authorization BIOLOGICALS FOR ARTHRITIS

FAX Completed Form To 1 (877) 733-3195 **Provider Help Desk**

S Iowa Health Link S Hawki

Patient address

Prescriber address

Pharmacy name

Pharmacy NPI

Failure reason:

Provider NPI

IA Medicaid Member ID #



(PLEASE PRINT – ACCURACY IS IMPORTANT)

1 (844) 236-1464 Patient name DOB Prescriber name Phone Fax Address Phone

NDC

Prior authorization is required for biologicals used for arthritis. Request must adhere to all FDA approved labeling for requested drug and indication, including age, dosing, contraindications, warnings and precautions, drug interactions, and use in specific populations. Payment for non-preferred biologicals for arthritis will be considered only for cases in which there is documentation of previous trials and therapy failures with two preferred biological The required trials may be overridden when documented evidence is provided that use of these agents would be medically contraindicated.

Prescriber must complete all information above. It must be legible, correct, and complete or form will be returned.

Pharmacy fax

Preferred Adalimumab-aacf Adalimumab-adbm Adalimumab-fkjp Amjevita 40mg/0.4mL Amjevita 80mg/0.8mL Enbrel Humira Kineret Orencia ClickJect Pyzchiva		Simlandi Simponi Skyrizi Auto-Injector Skyrizi Cartridge Skyrizi Prefilled Syringe Taltz (step through one Tremfya Tyenne Auto-Injector Yusimry	preferred TNF)	Mon-Preferred ☐ Actemra ☐ Bimzelx ☐ Cimzia (prefilled syringe) ☐ Cosentyx ☐ Ilaris ☐ Kevzara ☐ Orencia Prefilled Syringe ☐ Stelara ☐ Other Humira Biosimilar: ☐ Other Stelara Biosimilar:		
	Strength	Dosage Instructions	Quantity	Days Supply		
Rheumatoid arthritis (RA); with Documentation of a trial and inadequate response, at a maximally tolerated dose, with methotrexate (hydroxychloroquine, sulfasalazine, or leflunomide may be used if methotrexate is contraindicated).						
Drug Name &	Dose:		Trial dates:			

PAA-1017 (Rev. 6/25) Page 1 of 2

Request for Prior Authorization BIOLOGICALS FOR ARTHRITIS

(PLEASE PRINT - ACCURACY IS IMPORTANT)

☐ Psoriatic arthritis, moderate to severe; with Documentation of a trial and inadequate response, at a maximally tolera (leflunomide or sulfasalazine may be used if methotrexate is contraindic					
Drug Name &Dose:Trial dates:					
☐ Juvenile idiopathic arthritis with oligoarthritis; with					
Documentation of a trial and inadequate response to intraarticular glucomethotrexate at a maximally tolerated dose (leflunomide or sulfasalazin contraindicated).					
Intraarticular Glucocorticoid Injections: Drug Name & Dose:	Trial dates:				
Failure reason:					
Plus methotrexate or preferred oral DMARD trial: Drug Name & Dose: Trial dates: Failure reason: Polyarticular juvenile idiopathic arthritis (pJIA), moderate to severe; with					
Documentation of a trial and inadequate response, at a maximally tolerated dose, with methotrexate (leflunomide or sulfasalazine may be used if methotrexate is contraindicated).					
ug Name &Dose:Trial dates: ilure reason:					
Systemic juvenile idiopathic arthritis (sJIA) Reason for use of Non-Preferred drug requiring prior approval:					
Leason for use of Non-Freiened drug requiring prior approvai.					
Other medical conditions to consider:					
Prescriber signature (Must match prescriber listed above.)	Date of submission				

IMPORTANT NOTE: In evaluating requests for prior authorization the consultant will consider the treatment from the standpoint of medical necessity only. If approval of this request is granted, this does not indicate that the member continues to be eligible for Medicaid. It is the responsibility of the provider who initiates the request for prior authorization to establish by inspection of the member's Medicaid eligibility card and, if necessary by contact with the county Department of Health and Human Services, that the member continues to be eligible for Medicaid.

PAA-1017 (Rev. 6/25) Page 2 of 2